ORAGENICS INC (OGEN): M&A transaction — Oragenics completes acquisition of Odyssey's concussion, NPC drug assets for $1M cash + 8M preferred shares

ORAGENICS INC

Paid $1M cash and issued 8M Series F Preferred shares to Odyssey for assets including mTBI (concussion) and NPC drug candidates and nasal delivery device.
Joseph Michael Redmond appointed President with $396,000 base salary, eligible for 50% performance bonus, and 75,000 stock options at $5.40.
Kimberly Murphy remains CEO and board member; Redmond reports to her.
Series F Preferred is convertible into common stock; further details in prior 8-K from October 5, 2023.
Employment agreement has 1-year initial term with automatic renewal; severance includes 6-12 months base salary under certain conditions.

item 2.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph Michael Redmond

President

OGEN · ORAGENICS INC

Effective: 2023-12-28
Filed: December 29, 2023, 6:59 PM ET

the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Michael Redmond was appointed as President at ORAGENICS INC.

Action: appointed
Role: President

Exact text from the filing

the Company entered into an Executive Employment Agreement with Joseph Michael Redmond, pursuant to which he will serve as the President of the Company

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ORAGENICS INC completed an acquisition involving Odyssey Health, Inc., f/k/a Odyssey Group International, Inc. for $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).

Action: acquisition
Counterparty: Odyssey Health, Inc., f/k/a Odyssey Group International, Inc.
Consideration: $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock
Closing: 2023-12-28

Exact text from the filing

Pick Disease Type C (NPC), as well as Odyssey’s proprietary powder formulation and its nasal delivery device. In consideration for the Purchased Assets, the Company paid Odyssey $1,000,000 in cash and issued 8,000,000 shares of convertible Series F Preferred Stock to Odyssey. The Series F Preferred Stock is convertible into shares of the Company’s common stock, as

View on SEC.gov

24 m&a transactions filed in the last 30 days. Browse all m&a transactions →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-23-046468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.